“As previously announced, the second quarter was weaker than expected. Sales were negatively impacted by a temporary inventory adjustment by our single largest distributor. Underlying…
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation (HSCT). Building on the proven…
On Monday, July 20 at 09:00 a.m. CEST, Devyser Diagnostics AB will host an online presentation of its Q2 2026 report (which will have been published earlier on July 20 at 07:30 a.m.…
Devyser Diagnostics AB (publ) (the “Company” or the “Group”) announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and…
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes…
Devyser today announces that Sabina Berlin, current CFO, will transition to a new role with responsibility for Investor Relations and Corporate Compliance. At the same time, the company…
The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present…
On Monday April 27 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2026 report (which will have been published earlier on April 27 at 09:00 a.m.…
Devyser Diagnostics AB today announces that the company’s Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
“During…
